A 13 Mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-0489
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Phase I Trial of Isatuximab Monotherapy in the Treatment of Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Clinical Cancer Research
Cancer ResearchOncology
2015English

Characterizing Melphalan Efficacy and Toxicity in Multiple Myeloma Patients With Renal Insufficiency

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy